These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 3886826)

  • 1. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
    Rosenberg SA; Mulé JJ; Spiess PJ; Reichert CM; Schwarz SL
    J Exp Med; 1985 May; 161(5):1169-88. PubMed ID: 3886826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Mulé JJ
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ; Shu S; Rosenberg SA
    J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
    Mazumder A; Rosenberg SA
    J Exp Med; 1984 Feb; 159(2):495-507. PubMed ID: 6141211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
    Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
    J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
    Mulé JJ; Shu S; Schwarz SL; Rosenberg SA
    Science; 1984 Sep; 225(4669):1487-9. PubMed ID: 6332379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E; Ben-Aziz R; Shiloni E
    Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
    Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.
    Papa MZ; Vetto JT; Ettinghausen SE; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5618-23. PubMed ID: 3489525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.